摘要
间充质基质细胞(MSCs)作为一种具有自我增殖和多向分化潜能的细胞,已成为多种急、慢性疾病的潜在治疗方法。对于骨骼疾病,尤其是骨质疏松症、骨质疏松性骨折和骨缺损等,传统的治疗方法往往只能缓解症状,难以实现根本治愈。MSCs因其多向分化潜能、免疫调节特性及旁分泌功能,在骨质疏松症治疗与骨再生领域展现出巨大潜力。目前,多项MSCs治疗骨质疏松症的研究已进行到临床试验阶段。本文将梳理国内外相关文献,分析MSCs在骨质疏松症治疗与骨再生领域研究的相关现状,讨论未来可能的发展方向,旨在为今后参与骨质疏松症治疗临床前和临床研究的同道提供一些参考。
Mesenchymal stromal cells(MSCs),characterized by their self-renewal capacity and multilineage differentiation potential,have emerged as a promising therapeutic approach for various acute and chronic diseases.In the context of skeletal disorders,particularly osteoporosis,osteoporotic fractures,and osteoporotic bone defects,conventional treatments often only alleviate symptoms rather than achieving a fundamental cure.Owing to their multidirectional differentiation capability,immunomodulatory properties,and paracrine functions,MSCs havedemonstrated significant potential in the treatment of osteoporosis and bone regeneration.Currently,multiple clinical trials have been initiated to evaluate MSC-based therapies for osteoporosis.This article reviews relevant literature from both domestic and international sources,analyzes the current research status of MSCs in the treatment of osteoporosis and bone regeneration,and discusses potential future directions,aiming to provide insights for peers engaged in preclinical and clinical research on osteoporosis treatment.
作者
潘盛
王雄毅
沈旭雯
云思敏
徐又佳
Pan Sheng;Wang Xiongyi;Shen Xuwen;Yun Simin;Xu Youjia(Osteoporosis Clinical Center,Second Affiliated Hospital of Soochow University,Suzhou 215004,China;Department of Orthopedics,Second Affiliated Hospital of Soochow University,Suzhou 215004,China)
出处
《中华实验外科杂志》
2025年第11期2170-2175,共6页
Chinese Journal of Experimental Surgery
基金
江苏省医学骨质疏松重点实验室项目(JSDW202254)
国家自然科学基金(82372455)
中核医疗科技创新项目(ZHYLZD2023001)。
关键词
间充质基质细胞
骨质疏松症
骨再生
Mesenchymal stromal cells
Osteoporosis
Bone regeneration
